Neutrophil‐mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model

Abstract

Inhibition of VEGF signalling effectively suppresses localized tumour growth but accelerates tumour invasiveness and micrometastasis by unknown mechanisms. To study the dynamic and reciprocal interactions between tumour cells and their microenvironment during these processes, we established a xenograft model by injecting tumour cells into the blood circulation of transparent zebrafish embryos. This reproducibly results in rapid simultaneous formation of a localized tumour and experimental micrometastasis, allowing time‐resolved imaging of both processes at single‐cell resolution within 1 week. The tumour vasculature was initiated de novo by remodelling of primitive endothelial cells into a functional network. Roles of myeloid cells in critical tumourigenesis steps such as vascularization and invasion were revealed by genetic and pharmaceutical approaches. We discovered that the physiological migration of neutrophils controlled tumour invasion by conditioning the collagen matrix and forming the metastatic niche, as detected by two‐photon confocal microscopy and second harmonic generation. Administration of VEGFR inhibitors blocked tumour vascularization and a localized tumour growth but enhanced migration of neutrophils, which in turn promoted tumour invasion and formation of micrometastasis. This demonstrates the in vivo cooperation between VEGF signalling and myeloid cells in metastasis and provides a new mechanism underlying the recent findings that VEGFR targeting can promote tumour invasiveness. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 57

1. 1.

   Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.

   Not in our library10.1016/j.cell.2011.02.013

2. 2.

   Ebos J, Kerbel R. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8:210-221.

   Not in our library10.1038/nrclinonc.2011.21

3. 3.

   Plimack E, Tannir N, Lin E, et al. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer. 2009;115:1859-1866.

   Not in our library10.1002/cncr.24211

4. 4.

   Petrelli F, Cabiddu M, Carpo M, et al. Progression of intramedullary metastasis during perioperative cessation of sunitinib. Nat Rev Urol. 2010;7:634-637.

   Not in our library10.1038/nrurol.2010.161

5. 5.

   Desar I, Mulder S, Stillebroer A, et al. The reverse side of the victory: flare-up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol. 2009;48:927-931.

   Not in our library10.1080/02841860902974167

6. 6.

   Cacheux W, Boisserie T, Staudacher L, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol. 2008;19:1659-1661.

   Not in our library10.1093/annonc/mdn540

7. 7.

   Ebos J, Lee C, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239.

   Not in our library10.1016/j.ccr.2009.01.021

8. 8.

   Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.

   Not in our library10.1016/j.ccr.2009.01.027

9. 9.

   Levashova Z, Backer M, Hamby CV, et al. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med. 2010;51:959-966.

   Not in our library10.2967/jnumed.109.072199

10. 10.

    Nagengast WB, Lub-de Hooge MN, Oosting SF, et al. VEGF–PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res. 2011;71:143-153.

    Not in our library10.1158/0008-5472.can-10-1088

11. 11.

    Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272-7283.

    Not in our library10.1158/1078-0432.ccr-08-0652

12. 12.

    Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108:3749-3754.

    Not in our library10.1073/pnas.1014480108

13. 13.

    Patenaude A, Parker J, Karsan A. Involvement of endothelial progenitor cells in tumor vascularization. Microvasc Res. 2010;79:217-223.

    Not in our library10.1016/j.mvr.2010.01.007

14. 14.

    Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252.

    Not in our library10.1038/nrc2618

15. 15.

    Vecchiarelli-Federico LM, Cervi D, Haeri M, et al. Vascular endothelial growth factor—a positive and negative regulator of tumor growth. Cancer Res. 2010;70:863-867.

    Not in our library10.1158/0008-5472.can-09-3592

16. 16.

    Stockmann C, Doedens A, Weidemann A, et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature. 2008;456:814-818.

    Not in our library10.1038/nature07445

17. 17.

    Tlsty T, Coussens L. Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2006;1:119-150.

    Not in our library10.1146/annurev.pathol.1.110304.100224

18. 18.

    Shojaei F, Ferrara N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res. 2008;68:5501-5504.

    Not in our library10.1158/0008-5472.can-08-0925

19. 19.

    Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9:285-293.

    Not in our library10.1038/nrc2621

20. 20.

    Stoletov K, Klemke R. Catch of the day: zebrafish as a human cancer model. Oncogene. 2008;27:4509-4520.

    Not in our library10.1038/onc.2008.95

21. 21.

    Lieschke G, Trede N. Fish immunology. Curr Biol. 2009;19:R678-682.

    Not in our library10.1016/j.cub.2009.06.068

22. 22.

    Goessling W, North TE, Zon LI. New waves of discovery: modeling cancer in zebrafish. J Clin Oncol. 2007;25:2473-2479.

    Not in our library10.1200/jco.2006.08.9821

23. 23.

    North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447:1007-1011.

    Not in our library10.1038/nature05883

24. 24.

    Zon L, Peterson R. In vivo drug discovery in the zebrafish. Nat Rev Drug Discov. 2005;4:35-44.

    Not in our library10.1038/nrd1606

25. 25.

    Lawson N, Weinstein B. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol. 2002;248:307-318.

    Not in our library10.1006/dbio.2002.0711

26. 26.

    Renshaw SA, Loynes CA, Trushell DMI, et al. A transgenic zebrafish model of neutrophilic inflammation. Blood. 2006;108:3976-3978.

    Not in our library10.1182/blood-2006-05-024075

27. 27.
    Live Imaging of Innate Immune Cell Sensing of Transformed Cells in Zebrafish Larvae: Parallels between Tumor Initiation and Wound Inflammation · 2010

    Corrected
28. 28.

    Stoletov K, Montel V, Lester RD, et al. High-resolution imaging of the dynamic tumor cell vascular interface in transparent zebrafish. Proc Natl Acad Sci USA. 2007;104:17406-17411.

    Not in our library10.1073/pnas.0703446104

29. 29.

    Chen A, Zon L. Zebrafish blood stem cells. J Cell Biochem. 2009;108:35-42.

    Not in our library10.1002/jcb.22251

30. 30.

    Ellett F, Lieschke G. Zebrafish as a model for vertebrate hematopoiesis. Curr Opin Pharmacol. 2010;10:563-570.

    Not in our library10.1016/j.coph.2010.05.004

31. 31.

    Mathias JR, Dodd ME, Walters KB, et al. Live imaging of chronic inflammation caused by mutation of zebrafish Hai1. J Cell Sci. 2007;120:3372-3383.

    Not in our library10.1242/jcs.009159

32. 32.

    Rhodes J, Hagen A, Hsu K, et al. Interplay of pu.1 and gata1 determines myelo-erythroid progenitor cell fate in zebrafish. Dev Cell. 2005;8:97-108.

    Not in our library10.1016/j.devcel.2004.11.014

33. 33.

    Krens S, He S, Lamers G, et al. Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulation. Dev Biol. 2008;319:370-383.

    Not in our library10.1016/j.ydbio.2008.04.032

34. 34.

    Nicoli S, Ribatti D, Cotelli F, et al. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res. 2007;67:2927-2931.

    Not in our library10.1158/0008-5472.can-06-4268

35. 35.

    Deckers M, van Dinther M, Buijs J, et al. The tumor suppressor Smad4 is required for transforming growth factor-β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006;66:2202-2209.

    Not in our library10.1158/0008-5472.can-05-3560

36. 36.

    He S, Salas-Vidal E, Rueb S, et al. Genetic and transcriptome characterization of model zebrafish cell lines. Zebrafish. 2006;3:441-453.

    Not in our library10.1089/zeb.2006.3.441

37. 37.

    Haldi M, Ton C, Seng W, et al. Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis. 2006;9:139-151.

    Not in our library10.1007/s10456-006-9040-2

38. 38.

    Zoumi A, Yeh A, Tromberg BJ. Imaging cells and extracellular matrix in vivo by using second-harmonic generation and two-photon excited fluorescence. Proc Natl Acad Sci USA. 2002;99:11014-11019.

    Not in our library10.1073/pnas.172368799

39. 39.

    Mathias JR, Perrin BJ, Liu T-X, et al. Resolution of inflammation by retrograde chemotaxis of neutrophils in transgenic zebrafish. J Leukoc Biol. 2006;80:1281-1288.

    Not in our library10.1189/jlb.0506346

40. 40.

    He S, Krens S, Zhan H, et al. A Raf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. J Pathol. 2011;225:19-28.

    Not in our library10.1002/path.2936

Cited by papers we hold 7

• Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy · 2022
  Not checked
• The Use of Zebrafish Xenotransplant Assays to Analyze the Role of lncRNAs in Breast Cancer · 2021
  Not checked
• Zebrafish Models of Cancer—New Insights on Modeling Human Cancer in a Non-Mammalian Vertebrate · 2019
  No notice
• The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity · 2018
  No notice
• Postoperative Low Absolute Lymphocyte Counts may Predict Poor Outcomes of Hepatocellular Carcinoma After Liver Resection · 2016
  Not checked
• Hooking the big one: the potential of zebrafish xenotransplantation to reform cancer drug screening in the genomic era · 2014
  No notice
• From seeing to believing: labelling strategies for in vivo cell-tracking experiments · 2013
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.